Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions

Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for... Purpose To investigate whether targeted retinal photocoagulation (TRP) of peripheral non‐perfused areas (NPAs) could prevent the recurrence of macular oedema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal bevacizumab injection (IVB). Methods Eyes received 1.25 mg IVB only (IVB group) or combined with TRP (IVB + TRP group) of NPAs, more than 5 disc areas identified by fluorescein angiography in the patients with ME secondary to BRVO. Best‐corrected visual acuity (BCVA) and central retinal thickness (CRT) determined by optical coherence tomography were measured every month for 6 months. Results Thirty‐eight patients were enrolled and randomized to IVB group (n = 19) and IVB + TRP group (n = 19). Both groups showed similar thinning in CRT at 1 week after IVB, IVB + TRP group maintained thinner retina at 2 (p = 0.0072) and 3 (p = 0.0086) months compared with IVB group in whom turned to thickened almost back to baseline at 3 months. The number of reinjections in IVB group (1.58 ± 0.69) was significantly greater (p = 0.0025) than that in IVB + TRP group (0.83 ± 0.62). BCVA significantly improved at 6 month in IVB + TRP group (p = 0.015), but not in IVB group. Conclusion TRP of NPAs reduced the amount of ME recurrence following IVB compared to IVB alone. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Ophthalmologica Wiley

Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions

Download PDF
6 pages

Loading next page...
 
/lp/wiley/comparative-study-of-combined-bevacizumab-targeted-photocoagulation-vs-sy6MBgwi5y
Publisher
Wiley
Copyright
Copyright © 2016 Acta Ophthalmologica Scandinavica Foundation
ISSN
1755-375X
eISSN
1755-3768
DOI
10.1111/aos.12721
pmid
25989706
Publisher site
See Article on Publisher Site

Abstract

Purpose To investigate whether targeted retinal photocoagulation (TRP) of peripheral non‐perfused areas (NPAs) could prevent the recurrence of macular oedema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal bevacizumab injection (IVB). Methods Eyes received 1.25 mg IVB only (IVB group) or combined with TRP (IVB + TRP group) of NPAs, more than 5 disc areas identified by fluorescein angiography in the patients with ME secondary to BRVO. Best‐corrected visual acuity (BCVA) and central retinal thickness (CRT) determined by optical coherence tomography were measured every month for 6 months. Results Thirty‐eight patients were enrolled and randomized to IVB group (n = 19) and IVB + TRP group (n = 19). Both groups showed similar thinning in CRT at 1 week after IVB, IVB + TRP group maintained thinner retina at 2 (p = 0.0072) and 3 (p = 0.0086) months compared with IVB group in whom turned to thickened almost back to baseline at 3 months. The number of reinjections in IVB group (1.58 ± 0.69) was significantly greater (p = 0.0025) than that in IVB + TRP group (0.83 ± 0.62). BCVA significantly improved at 6 month in IVB + TRP group (p = 0.015), but not in IVB group. Conclusion TRP of NPAs reduced the amount of ME recurrence following IVB compared to IVB alone.

Journal

Acta Ophthalmologica – Wiley

Published: May 1, 2016

Keywords: ; ; ; ; ; ; ; ;

References

  • Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion
    Arnarsson, Arnarsson; Stefánsson, Stefánsson
  • Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema
    Avitabile, Avitabile; Longo, Longo; Reibaldi, Reibaldi
  • Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients
    Beer, Beer; Wong, Wong; Hammad, Hammad; Falk, Falk; O'Malley, O'Malley; Khan, Khan
  • Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator
    Campochiaro, Campochiaro; Hafiz, Hafiz; Shah, Shah
  • Ranibizumab for macular edema following branch retinal vein occlusion: six‐month primary end point results of a phase III study
    Campochiaro, Campochiaro; Heier, Heier; Feiner, Feiner; Gray, Gray; Saroj, Saroj; Rundle, Rundle; Murahashi, Murahashi; Rubio, Rubio
  • Long‐term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study
    Campochiaro, Campochiaro; Sophie, Sophie; Pearlman, Pearlman
  • Treatment of branch retinal vein occlusion induced macular edema in treatment‐naive cases with a single intravitreal triamcinolone or bevacizumab injection
    Chen, Chen; Chen, Chen; Wu, Wu; Chen, Chen; Lee, Lee; Liu, Liu; Kuo, Kuo
  • Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion
    Chung, Chung; Hong, Hong; Lee, Lee; Kwon, Kwon; Koh, Koh
  • Retinal vein occlusion: beyond the acute event
    Ehlers, Ehlers; Fekrat, Fekrat
  • Results of bevacizumab as the primary treatment for retinal vein occlusions
    Figueroa, Figueroa; Contreras, Contreras; Noval, Noval; Arruabarrena, Arruabarrena
  • Prognostic factors for retinal vein occlusion: prospective study of 175 cases
    Glacet‐Bernard, Glacet‐Bernard; Coscas, Coscas; Chabanel, Chabanel; Zourdani, Zourdani; Lelong, Lelong; Samama, Samama
  • Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion
    Higashiyama, Higashiyama; Sawada, Sawada; Kakinoki, Kakinoki; Sawada, Sawada; Kawamura, Kawamura; Ohji, Ohji
  • Retinal vein occlusions
    Jonas, Jonas; Paques, Paques; Mones, Mones; Glacet‐Bernard, Glacet‐Bernard
  • Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the phase 3 GALILEO study
    Korobelnik, Korobelnik; Holz, Holz; Roider, Roider
  • Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion
    Koss, Koss; Pfister, Pfister; Rothweiler, Rothweiler; Michaelis, Michaelis; Cinatl, Cinatl; Schubert, Schubert; Koch, Koch
  • Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion
    Kreutzer, Kreutzer; Alge, Alge; Wolf, Wolf
  • Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
    Kriechbaum, Kriechbaum; Michels, Michels; Prager, Prager; Georgopoulos, Georgopoulos; Funk, Funk; Geitzenauer, Geitzenauer; Schmidt‐Erfurth, Schmidt‐Erfurth
  • Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study
    Lopez‐Garcia, Lopez‐Garcia; Garcia‐Lozano, Garcia‐Lozano; Rivas, Rivas; Ramirez, Ramirez; Raposo, Raposo; Mendez, Mendez
  • Optos‐guided pattern scan laser (Pascal)‐targeted retinal photocoagulation in proliferative diabetic retinopathy
    Muqit, Muqit; Marcellino, Marcellino; Henson, Henson; Young, Young; Patton, Patton; Charles, Charles; Turner, Turner; Stanga, Stanga
  • Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin‐6
    Noma, Noma; Funatsu, Funatsu; Yamasaki, Yamasaki
  • Influence of ischaemia on visual function in patients with branch retinal vein occlusion and macular edema
    Noma, Noma; Funatsu, Funatsu; Mimura, Mimura; Shimada, Shimada
  • Changes of aqueous vascular endothelial growth factor and interleukin‐6 after intravitreal triamcinolone for branch retinal vein occlusion
    Park, Park; Ahn, Ahn
  • Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six‐month results of a prospective randomized clinical trial
    Pielen, Pielen; Mirshahi, Mirshahi; Feltgen, Feltgen
  • Ultra wide‐field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion
    Prasad, Prasad; Oliver, Oliver; Coffee, Coffee; Hubschman, Hubschman; Schwartz, Schwartz
  • Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion
    Rabena, Rabena; Pieramici, Pieramici; Castellarin, Castellarin; Nasir, Nasir; Avery, Avery
  • Branch retinal vein occlusion. Axial length and other risk factors
    Simons, Simons; Brucker, Brucker
  • Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case‐control study
    Sperduto, Sperduto; Hiller, Hiller; Chew, Chew
  • The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection
    Takamura, Takamura; Tomomatsu, Tomomatsu; Matsumura, Matsumura; Arimura, Arimura; Gozawa, Gozawa; Takihara, Takihara; Inatani, Inatani
  • Clinical practice. Retinal‐vein occlusion
    Wong, Wong; Scott, Scott
  • Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months
    Wu, Wu; Arevalo, Arevalo; Berrocal, Berrocal; Maia, Maia; Roca, Roca; Morales‐Canton, Morales‐Canton; Alezzandrini, Alezzandrini; Diaz‐Llopis, Diaz‐Llopis
  • Intravitreal aflibercept (eylea): a review of its use in patients with macular oedema secondary to central retinal vein occlusion
    Yang, Yang; McKeage, McKeage